Nodal marginal zone B-cell lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma, characterized by abnormal clonal proliferation of mature B-lymphocytes with involvement of the lymph nodes, sometim...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding nodal marginal zone B-cell lymphoma is limited due to its rarity, with a prevalence of only 1-9 in 100,000 individuals. This extreme rarity restricts the number of systematic clinical studies and comprehensive characterizations of the disease. Additionally, the lack of identified genetic factors and established inheritance patterns contributes to the challenges in understanding NMZL fully.
To navigate your diagnosis of nodal marginal zone B-cell lymphoma, consider consulting a hematologist or an oncologist who specializes in lymphomas. They can provide insights into treatment options and clinical trials. While there are currently no patient organizations specifically for NMZL, you may find support through broader lymphoma advocacy groups. Additionally, you can explore participation in clinical trials, which may offer access to new therapies. For resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov for further information.
There are several orphan drug designations for NMZL, including FDA-approved treatments such as ibrutinib, lenalidomide, and umbralisib. In development, drugs like axicabtagene ciloleucel and idelalisib are being explored. Currently, there are 15 active clinical trials investigating various aspects of NMZL. For more information, you can search for ongoing studies at ClinicalTrials.gov using this link: https://clinicaltrials.gov/search?cond=nodal%20marginal%20zone%20B-cell%20lymphoma.
Actionable guidance for navigating care for nodal marginal zone B-cell lymphoma
To navigate your diagnosis of nodal marginal zone B-cell lymphoma, consider consulting a hematologist or an oncologist who specializes in lymphomas. They can provide insights into treatment options and clinical trials. While there are currently no patient organizations specifically for NMZL, you may find support through broader lymphoma advocacy groups. Additionally, you can explore participation in clinical trials, which may offer access to new therapies. For resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov for further information.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding nodal marginal zone B-cell lymphoma is limited due to its rarity, with a prevalence of only 1-9 in 100,000 individuals. This extreme rarity restricts the number of systematic clinical studies and comprehensive characterizations of the disease. Additionally, the lack of identified genetic factors and established inheritance patterns contributes to the challenges in understanding NMZL fully.
To navigate your diagnosis of nodal marginal zone B-cell lymphoma, consider consulting a hematologist or an oncologist who specializes in lymphomas. They can provide insights into treatment options and clinical trials. While there are currently no patient organizations specifically for NMZL, you may find support through broader lymphoma advocacy groups. Additionally, you can explore participation in clinical trials, which may offer access to new therapies. For resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov for further information.
There are several orphan drug designations for NMZL, including FDA-approved treatments such as ibrutinib, lenalidomide, and umbralisib. In development, drugs like axicabtagene ciloleucel and idelalisib are being explored. Currently, there are 15 active clinical trials investigating various aspects of NMZL. For more information, you can search for ongoing studies at ClinicalTrials.gov using this link: https://clinicaltrials.gov/search?cond=nodal%20marginal%20zone%20B-cell%20lymphoma.
Actionable guidance for navigating care for nodal marginal zone B-cell lymphoma
To navigate your diagnosis of nodal marginal zone B-cell lymphoma, consider consulting a hematologist or an oncologist who specializes in lymphomas. They can provide insights into treatment options and clinical trials. While there are currently no patient organizations specifically for NMZL, you may find support through broader lymphoma advocacy groups. Additionally, you can explore participation in clinical trials, which may offer access to new therapies. For resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov for further information.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding nodal marginal zone B-cell lymphoma is limited due to its rarity, with a prevalence of only 1-9 in 100,000 individuals. This extreme rarity restricts the number of systematic clinical studies and comprehensive characterizations of the disease. Additionally, the lack of identified genetic factors and established inheritance patterns contributes to the challenges in understanding NMZL fully.
To navigate your diagnosis of nodal marginal zone B-cell lymphoma, consider consulting a hematologist or an oncologist who specializes in lymphomas. They can provide insights into treatment options and clinical trials. While there are currently no patient organizations specifically for NMZL, you may find support through broader lymphoma advocacy groups. Additionally, you can explore participation in clinical trials, which may offer access to new therapies. For resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov for further information.
There are several orphan drug designations for NMZL, including FDA-approved treatments such as ibrutinib, lenalidomide, and umbralisib. In development, drugs like axicabtagene ciloleucel and idelalisib are being explored. Currently, there are 15 active clinical trials investigating various aspects of NMZL. For more information, you can search for ongoing studies at ClinicalTrials.gov using this link: https://clinicaltrials.gov/search?cond=nodal%20marginal%20zone%20B-cell%20lymphoma.
Actionable guidance for navigating care for nodal marginal zone B-cell lymphoma
To navigate your diagnosis of nodal marginal zone B-cell lymphoma, consider consulting a hematologist or an oncologist who specializes in lymphomas. They can provide insights into treatment options and clinical trials. While there are currently no patient organizations specifically for NMZL, you may find support through broader lymphoma advocacy groups. Additionally, you can explore participation in clinical trials, which may offer access to new therapies. For resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov for further information.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 13 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning nodal marginal zone B-cell lymphoma
Updated Dec 4, 2025
FDA approves Breyanzi (lisocabtagene maraleucel) as the first CAR T-cell therapy for marginal zone lymphoma in the U.S. This approval marks a significant advancement in treatment options for patients with this rare blood cancer.